Danaher Co. (NYSE:DHR) Shares Acquired by Trust Investment Advisors

Trust Investment Advisors boosted its stake in shares of Danaher Co. (NYSE:DHR) by 1.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,811 shares of the conglomerate’s stock after purchasing an additional 49 shares during the quarter. Trust Investment Advisors’ holdings in Danaher were worth $650,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in DHR. Calamos Advisors LLC increased its position in Danaher by 36.2% in the 4th quarter. Calamos Advisors LLC now owns 329,902 shares of the conglomerate’s stock valued at $76,320,000 after acquiring an additional 87,658 shares during the period. Xponance Inc. grew its stake in shares of Danaher by 9.6% in the fourth quarter. Xponance Inc. now owns 94,101 shares of the conglomerate’s stock worth $21,769,000 after purchasing an additional 8,252 shares in the last quarter. AIA Group Ltd increased its holdings in shares of Danaher by 614.2% during the fourth quarter. AIA Group Ltd now owns 153,827 shares of the conglomerate’s stock valued at $35,586,000 after purchasing an additional 132,289 shares during the period. SFE Investment Counsel boosted its stake in shares of Danaher by 40.7% during the 4th quarter. SFE Investment Counsel now owns 12,670 shares of the conglomerate’s stock worth $2,931,000 after acquiring an additional 3,665 shares in the last quarter. Finally, Cambridge Trust Co. grew its holdings in shares of Danaher by 1.7% in the 4th quarter. Cambridge Trust Co. now owns 74,438 shares of the conglomerate’s stock worth $17,221,000 after acquiring an additional 1,233 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, SVP Daniel Raskas sold 23,757 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the sale, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction on Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the sale, the senior vice president now owns 38,102 shares in the company, valued at approximately $9,601,704. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Teri List sold 3,289 shares of the firm’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the sale, the director now directly owns 19,726 shares of the company’s stock, valued at approximately $4,898,360.32. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 32,957 shares of company stock worth $8,265,802. Corporate insiders own 11.10% of the company’s stock.

Wall Street Analysts Forecast Growth

DHR has been the topic of several recent research reports. Raymond James lifted their price objective on Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Royal Bank of Canada upped their target price on shares of Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. JPMorgan Chase & Co. raised their price target on shares of Danaher from $250.00 to $270.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 20th. HSBC upgraded Danaher from a “hold” rating to a “buy” rating and upped their price objective for the company from $250.00 to $280.00 in a research note on Wednesday. Finally, StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Six investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $268.27.

Danaher Trading Down 1.3 %

DHR stock traded down $3.03 during midday trading on Thursday, reaching $236.36. The stock had a trading volume of 4,235,840 shares, compared to its average volume of 2,727,856. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $259.00. The firm has a market cap of $175.03 billion, a price-to-earnings ratio of 37.46, a PEG ratio of 3.65 and a beta of 0.83. The business has a fifty day simple moving average of $249.28 and a two-hundred day simple moving average of $229.86.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.18. The firm had revenue of $6.41 billion during the quarter, compared to analyst estimates of $6.10 billion. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The business’s quarterly revenue was down 10.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.87 EPS. As a group, research analysts expect that Danaher Co. will post 7.62 EPS for the current fiscal year.

Danaher Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be paid a $0.27 dividend. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.46%. This is a positive change from Danaher’s previous quarterly dividend of $0.24. Danaher’s payout ratio is presently 16.90%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.